Can hydrogen therapy help with COPD symptoms?

This rat study suggests hydrogen gas therapy may help reduce COPD inflammation by reprogramming immune cells. However, human clinical trials are needed to confirm these benefits in people.

How does hydrogen gas reduce lung inflammation?

Hydrogen appears to shift harmful inflammatory immune cells (M1 macrophages) into helpful healing cells (M2 macrophages). This reduces inflammatory chemicals and increases protective substances in the lungs.

What did researchers find about hydrogen and COPD?

Rats with COPD-like symptoms who received hydrogen gas for 14 days showed improved lung function, reduced inflammation, and less tissue damage compared to untreated rats.

Is hydrogen gas therapy safe for lung conditions?

Hydrogen gas is generally considered safe with no known toxic effects. However, this study was done in rats, so safety and effectiveness in humans with COPD requires further research.

How was hydrogen gas given to the rats in this study?

The rats received hydrogen gas therapy for 2 hours per day for 14 days. The study doesn't specify the exact delivery method or concentration used.

Hydrogen Gas Reduces Lung Inflammation in COPD Rats

Authors: Jing-Chao Su, Yi Zhang, Chen Cheng, Yi-Nan Zhu, Yu-Meng Ye, Yong-Kang Sun, Shui-Ying Xiang, Yuan Wang, Zi-Bing Liu, Xin-Fang Zhang
Journal: Experimental Lung Research
Year: 2021
DOI: 10.1080/01902148.2021.1919788
Study Type: Rat
Outcome: Positive
Peer Reviewed: Yes
Country: China
Health Condition: Chronic Obstructive Pulmonary Disease (COPD)
Body System: Respiratory

TL;DR

Hydrogen gas therapy improved lung function and reduced inflammation in rats with a lung condition similar to COPD by influencing the behavior of immune cells in the lungs.

Key Finding

Hydrogen gas treatment improved lung function and reduced inflammation in rats with COPD-like disease by shifting immune cells in the lungs from a pro-inflammatory to an anti-inflammatory state.

Summary

Researchers gave rats with a disease similar to human COPD (a serious lung condition) hydrogen gas to breathe for 2 hours daily over 14 days. They found that hydrogen treatment improved lung function and reduced inflammation by changing how immune cells in the lungs behave—specifically, it shifted these cells from a pro-inflammatory state (which causes damage) to an anti-inflammatory state (which reduces damage). The hydrogen appeared to work by lowering harmful inflammatory chemicals and raising protective ones.

Practical Takeaway

This rat study suggests hydrogen gas may help reduce lung inflammation in COPD through a specific immune mechanism, but it is early-stage research in animals only. Human studies would be needed to determine if these effects occur in people with COPD and whether hydrogen therapy could be a practical treatment option.

Abstract

Chronic obstructive pulmonary disease (COPD) is a respiratory disease with high morbidity and mortality worldwide, so far there is no ideal treatment method. Previous studies have shown that hydrogen (H2) is involved in the treatment of COPD as an antioxidant. In this study, the effect of H2 on M1/M2 polarization of alveolar macrophages in COPD rats was observed, and its anti-inflammatory mechanism was further elucidated. Methods: Twenty-four Sprague-Dawley rats were randomly divided into three groups including the control, COPD and H2 group. A rat model of COPD was established by cigarette exposure combined with lipopolysaccharide (LPS) induction. H2 therapy was administered 2 hours per day for 14 days. Lung function and pathology were assessed. The levels of interleukin (IL)-6, tumor necrosis factor (TNF)-α, transforming growth factor (TGF)-β1 and IL-10 in bronchoalveolar lavage fluid (BALF) and lung tissue were measured by enzyme-linked immunosorbent assay. The mRNA, protein expression and immunoreactivity of inducible nitric oxide synthase (iNOS) and arginase (Arg)-1 in lung were observed by quantitative real-time PCR, western blot and immunohistochemistry. Results: Compared with the control rats, there were a significant decline in lung function, a marked inflammatory infiltration and pulmonary parenchymal remodeling and the increases of IL-6, TNF-α and TGF-β1 levels in BALF and lung tissue, but a lower expression of IL-10 in COPD rats. The iNOS mRNA and protein expression, as well as its optical density (OD), were increased significantly in lung tissue, while those of Arg-1 decreased significantly. H2 treatment improved the lung function and the parenchymal inflammation, reversed the increased levels of IL-6, TNF-α and TGF-β1, and the lower IL-10. Meanwhile, H2 also down-regulated the expression of iNOS, but up-regulated expression of Arg-1 in lung tissue. Conclusion: H2 reduces inflammation in the lung of COPD, which may be related to its inhibition of M1 type polarization and activation of M2 type polarization of alveolar macrophage.